Search research articles
Contact Us
Filters
Showing results (41-50 of 85) with videos related to
Page
of 9
Sort By:
Bone Marrow Research
|
May 31, 2014
Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
Anu Batra, Michele Cottler-Fox, Terry Harville, et al.
Cancer Biology & Therapy
|
April 23, 2016
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
Fade Mahmoud, Bradley Shields, Issam Makhoul, et al.
Reviews on Recent Clinical Trials
|
February 28, 2015
Defining and managing expectations for early immunotherapy cancer trials
Thomas Kieber-Emmons, Angela Pennisi, Anna Lane, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
|
June 26, 2018
Thinking Cancer
Anastas Pashov, Cinthia Violeta Hernandez Puente, Saddam Mohammed Ibrahim, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
June 20, 2017
Do checkpoint inhibitors rely on gut microbiota to fight cancer?
Belal Firwana, Nathan Avaritt, Bradley Shields, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
Valentina K Todorova, Stephanie D Byrum, Allen J Gies, et al.
Oncology Research
|
March 4, 2017
Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Valentina K Todorova, Issam Makhoul, Ishwori Dhakal, et al.
The Permanente Journal
|
February 26, 2020
Immunotherapy Outcomes in Advanced Melanoma in Relation to Age
Krishna Joshi, Dinesh Atwal, Rahul Ravilla, et al.
Plos One
|
December 5, 2012
Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model
Valentina K Todorova, Marjorie L Beggs, Robert R Delongchamp, et al.
Journal of Clinical Apheresis
|
July 22, 2014
Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor
Soumya Pandey, Mayumi Nakagawa, Eric R Rosenbaum, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 85) with videos related to
Sort By:
Page
of 9
Bone Marrow Research
|
May 31, 2014
Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma
Anu Batra, Michele Cottler-Fox, Terry Harville, et al.
Cancer Biology & Therapy
|
April 23, 2016
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis
Fade Mahmoud, Bradley Shields, Issam Makhoul, et al.
Reviews on Recent Clinical Trials
|
February 28, 2015
Defining and managing expectations for early immunotherapy cancer trials
Thomas Kieber-Emmons, Angela Pennisi, Anna Lane, et al.
Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
|
June 26, 2018
Thinking Cancer
Anastas Pashov, Cinthia Violeta Hernandez Puente, Saddam Mohammed Ibrahim, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
June 20, 2017
Do checkpoint inhibitors rely on gut microbiota to fight cancer?
Belal Firwana, Nathan Avaritt, Bradley Shields, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2022
Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer
Valentina K Todorova, Stephanie D Byrum, Allen J Gies, et al.
Oncology Research
|
March 4, 2017
Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
Valentina K Todorova, Issam Makhoul, Ishwori Dhakal, et al.
The Permanente Journal
|
February 26, 2020
Immunotherapy Outcomes in Advanced Melanoma in Relation to Age
Krishna Joshi, Dinesh Atwal, Rahul Ravilla, et al.
Plos One
|
December 5, 2012
Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model
Valentina K Todorova, Marjorie L Beggs, Robert R Delongchamp, et al.
Journal of Clinical Apheresis
|
July 22, 2014
Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor
Soumya Pandey, Mayumi Nakagawa, Eric R Rosenbaum, et al.
Page
of 9